Literature DB >> 9987157

Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant.

L A Hilgers1, G Lejeune, I Nicolas, M Fochesato, B Boon.   

Abstract

Previously, we described synergistic adjuvanticity of combinations of synthetic sulfolipo(SL)-derivatives of polysaccharide (SL-polysaccharides) and squalane-in-water emulsions (squalane/W). In this paper, effects of type of polysaccharide and nature of oil on adjuvanticity, reactogenicity and stability are described. SL-derivatives of the following polysaccharides were synthesised: synthetic polysucroses with weight-average molecular weight (MW) of 400,000 (Ficoll400), 70,000 (Ficoll70) and 39,000 Da (Ficoll39), polyfructose of 5,000 Da (inulin), linear polyglucose of 1,200 Da (maltodextrin) and cyclic polyglucose of 1,135 Da (beta-cyclodextrin). The number of sulphate groups per monosaccharide of the different SL-polysaccharides varied between 0.15 and 0.23 and the number of lipid groups per monosaccharide between 1.15 and 1.29. Adjuvant formulations were prepared by incorporating these SL-polysaccharides into oil-in-water emulsions of either squalane, hexadecane, soya oil or mineral oil. Adjuvanticity of the formulations obtained for humoral responses to inactivated pseudorabies virus (PRV) and inactivated influenza virus strains A/Swine (A/Swine) and MRC-11 (MRC-11) in pigs and MRC-11 and ovalbumin (OVA) in mice depended on the type of oil (squalane = mineral oil > hexadecane = soya oil) but not on the type of polysaccharide backbone of the SL-derivative. Reactogenicity assessed by local swelling in mice decreased with decreasing MW (SL-Ficoll400 = Ficoll70 = Ficoll39 > SL-inulin = SL-maltodextrin > SL-cyclodextrin) when combined with squalane and decreased with the type of oil in the following order: squalane > mineral oil > hexadecane > soya oil when combined with SL-Ficoll400. Stability of the SL-polysaccharide/squalane/W emulsions at elevated temperature increased with decreasing MW of the SL-polysaccharide (SL-Ficoll400 < SL-Ficoll70 = SL-Ficoll39 < SL-inulin = SL-maltodextrin = SL-cyclodextrin). SL-cyclodextrin/squalane/W remained stable for > 2.5 years at 4 degrees C, > 18 weeks at 37 degrees C and > 10 days at 60 degrees C. We concluded that reactogenicity and stability but not adjuvanticity of SL-polysaccharide/squalane/W formulations depended on the MW of SL-polysaccharide and that SL-cyclodextrin/squalane/W is a promising non-mineral oil adjuvant as it combines strong adjuvanticity (i.e. better than the mineral oil-based adjuvant presently applied) with low reactogenicity and good stability.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9987157     DOI: 10.1016/s0264-410x(98)00195-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Protective antiviral immune responses to pseudorabies virus induced by DNA vaccination using dimethyldioctadecylammonium bromide as an adjuvant.

Authors:  Eugene M A van Rooij; Harrie L Glansbeek; Luuk A T Hilgers; Eddie G te Lintelo; Yolanda E de Visser; Wim J A Boersma; Bart L Haagmans; Andre T J Bianchi
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 2.  Squalene emulsions for parenteral vaccine and drug delivery.

Authors:  Christopher B Fox
Journal:  Molecules       Date:  2009-09-01       Impact factor: 4.411

3.  Viral vaccine meeting held in Barcelona, October 25-28, 2003.

Authors:  A C M Boon; S Plotkin; G F Rimmelzwaan; A D M E Osterhaus
Journal:  Vaccine       Date:  2004-03-29       Impact factor: 3.641

Review 4.  Cyclodextrins in Antiviral Therapeutics and Vaccines.

Authors:  Susana Santos Braga; Jéssica S Barbosa; Nádia E Santos; Firas El-Saleh; Filipe A Almeida Paz
Journal:  Pharmaceutics       Date:  2021-03-19       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.